90. 網膜色素変性症
[臨床試験数:103,薬物数:158(DrugBank:42),標的遺伝子数:52,標的パスウェイ数:107

Searched query = "Retinitis pigmentosa", "Rod dystrophy", "Rod-Cone Dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04355689
(ClinicalTrials.gov)
September 3, 202017/4/2020Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher SyndromeSafety and Efficacy of NPI-001 Tablets Versus Placebo for Treatment of Retinitis Pigmentosa Associated With Usher SyndromeUsher SyndromesDrug: NPI-001;Other: PlaceboNacuity Pharmaceuticals, Inc.Foundation Fighting BlindnessRecruiting18 YearsN/AAll48Phase 1;Phase 2Australia
2NCT03999021
(ClinicalTrials.gov)
June 24, 201924/6/2019FIGHT-RP 1 Extension StudyA Phase 1 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis PigmentosaRetinitis PigmentosaDrug: NAC effervescent tabletsJohns Hopkins UniversityNULLActive, not recruiting18 YearsN/AAll30Phase 1United States
3NCT03063021
(ClinicalTrials.gov)
February 15, 201716/2/2017The FIGHT-RP1 StudyA Phase 1 Open Label Dose Ranging Study to Assess the Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa (FIGHT-RP1 Study)Retinitis PigmentosaDrug: N-Acetyl Cysteine (NAC)Johns Hopkins UniversityNULLCompleted18 YearsN/AAll30Phase 1United States